Dr Reddys Laboratories Ltd (DRREDDY) Q1 FY27 Earnings Call: Reiterates 20% EBITDA Margin for Q2, Semaglutide Supply to Resume in November

Dr Reddys Laboratories Ltd held its Q1 FY27 earnings call on July 22, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue decline masks double-digit base business momentum

• Consolidated revenue of Rs.8,071 Cr (USD 853M) — down 5.6% YoY but up 7.4% sequentially in Q1 FY 2026-2027, with the YoY decline driven by lower lenalidomide sales and a Rs.240 Cr semaglutide provision.
• EBITDA margin of 12.5% — excluding the semaglutide provision and related costs, adjusted margin was 15.4%; management estimated the adjusted margin at ~18% (high teens) when also excluding Middle East conflict impacts.
• Profit after tax of Rs.443 Cr (USD 47M) — representing a 5.5% margin; diluted EPS of Rs.5.32 in Q1 FY 2026-2027, with an effective tax rate of 21.3% benefiting from a reversal of previously recognized tax provisions.
• Gross profit margin of 46.5% — down 1,039 bps YoY, impacted by lower lenalidomide sales, the semaglutide provision, and higher solvent costs from the Middle East conflict.
• SG&A of Rs.2,082 Cr — up 12% YoY, with 75–80% of the increase attributed to adverse forex rate movements and elevated freight costs; management expects absolute SG&A (ex-R&D) for FY 2026-2027 to be broadly in line with FY 2025-2026 actuals.
• R&D spend of Rs.577 Cr (7.1% of revenue) — down 8% YoY due to lower bio-similar development expenditure; full-year FY 2026-2027 R&D guided at 7–8% of sales.
• Net cash surplus of Rs.3,057 Cr (USD 323M) — with operating working capital of Rs.14,353 Cr as of June 30, 2026, down Rs.81 Cr from March 31, 2026.

Supply halt triggers Rs.240 Cr provision; November resumption targeted

• 1,80,000 semaglutide pens sold in Q1 FY 2026-2027 — primarily for Canada and India, before a quality-related supply halt; a Rs.240 Cr provision was taken for unused material and batches, with no patient safety risk identified.
• API testing to complete by third week of September 2026 — supply to partner OneSource expected to resume by November 2026, targeting 6–7 million pens between November 2026 and March 2027, down from the earlier 10–11 million target.
• Lost opportunity of 3–4 million pens — due to the 4-month supply interruption; management expressed high confidence in demand post-resumption, citing approvals in multiple markets and strong partner engagements beyond Canada.
• Filed in ~30 countries out of a planned 80 — CEO Erez Israeli confirmed the long-term program is unchanged; Brazil approval expected within a few weeks (Q2 FY 2026-2027).
• Canada generic market share expectation of ~60% at launch — with potential to grow as confidence and supply increase; the analyst’s assumption of 80–90% share for FY 2027-2028 was not endorsed by management.
• Supply arrangement with Sandoz in Canada still holds — management expects to meet commitments upon resumption; no penalty claims are expected for supply failures to Sandoz and Aspen based on contractual terms as of Q1 FY 2026-2027.
• API capacity of >300 tonnes without scale-up — theoretical up to 550 tonnes; quality remains the primary focus; the API scale-up issue will not delay regulatory reviews since product specs remain unchanged.

Abatacept PDUFA in December 2026; biologics segment at 2% of revenue

• Abatacept BLA with PDUFA goal date of December 2026 (Q3 FY 2026-2027) — the Bachupally facility inspection yielded 7 observations, described as "very different" from prior inspection and addressable; management submitted the response on time and believes approval should follow.
• US IV biosimilar PDUFA goal date of December 2026 — launch possible upon approval; US sub-Q biosimilar launch expected around February/March 2028 (Q4 FY 2027-2028).
• European sub-Q biosimilar launch expected around September/October 2028 (Q2 FY 2028-2029) — the European IV biosimilar is filed but described as "very small" due to the market being primarily sub-Q.
• Rituximab biosimilar filing includes data for interchangeability — CEO Erez Israeli stated the product "will be interchangeable" upon approval, but USFDA inspection delays at the company's facility caused the approval delay as of Q1 FY 2026-2027.
• Denosumab BLA stalled due to partner's facility issues — the partner has addressed FDA observations, but management is currently "in discussions with the partner on what to do with this product" and has not yet resubmitted the BLA as of Q1 FY 2026-2027.
• Biologics sales represent 2% of global revenue — management expects the biologics segment to break even upon biosimilar launch; biologic and peptide facilities are not yet revenue-generating, with associated costs already hitting the P&L.

India and Emerging Markets lead growth; US base business shows resilience

• North America generics revenue of USD 236M — down 41% YoY (due to lower lenalidomide) but up 19% sequentially in Q1 FY 2026-2027; the underlying base business grew double-digit, with management maintaining double-digit growth guidance for the full year excluding semaglutide and lenalidomide.
• India business revenue of Rs.1,788 Cr — up 17% YoY and 10% QoQ in Q1 FY 2026-2027; organic growth (excluding acquisitions) was 15.5%, with semaglutide supply contributing minimally to that figure.
• Emerging markets revenue of Rs.1,833 Cr — up 31% YoY and 2% QoQ in Q1 FY 2026-2027, the strongest geographic growth in the quarter.
• Europe (incl. NRT) revenue of USD 131M — flat YoY and down 3% sequentially in Q1 FY 2026-2027; the NRT decline was attributed to inventory cutoffs and Brazil tender timing, though the underlying trend is growth, with EBITDA margin above company average.
• PSAI (API) revenue of USD 91M — down 5% YoY and 10% sequentially in Q1 FY 2026-2027.
• North America annualizing at ~$950M — down from ~$1B in FY 2021-2022 despite launching 90–100 products and a ~$100M acquisition over four years; management attributed the muted growth to double-digit (some years) and single-digit price erosion in the US generic market.
• Bosutinib launch with 400 mg dose exclusivity — less than one month of sales in Q1 FY 2026-2027, with only two weeks of supply; the 400 mg product market size is described as "large" (in billions of dollars), and the margin is above the company average.

20% EBITDA margin target reiterated for Q2; cost efficiency programs underway

• Adjusted EBITDA margin of ~18% in Q1 FY 2026-2027 — excluding semaglutide and Middle East impacts; management reiterated the 20% EBITDA margin guidance in the near term, expecting to achieve it in Q2 FY 2026-2027 even without semaglutide.
• With semaglutide returning in November (Q3 FY 2026-2027) — margins would be higher than 20%, per management.
• Productivity measures targeting a 10–12% gap — between revenue growth (double-digit, north of 15% in some emerging markets) and cost growth (low single-digit); this differential is already visible and expected to become more pronounced over time.
• Capex guidance of ~Rs.1,800 Cr for FY 2026-2027 — down from the previous range of Rs.2,500–Rs.2,700 Cr; management expects capex to stay at that level for FY 2027-2028.
• Combined EBITDA impact of ~1% from Middle East conflict and freight costs — for FY 2026-2027, expected to persist at least until December 2026.
• No PLI recognized in Q1 FY 2026-2027 — any meaningful PLI in the remaining nine months is contingent on semaglutide supply resumption and achieving minimum growth for setup products.
• Normalized tax rate for FY 2026-2027 guided at 24–25% — Q1 FY 2026-2027 benefited from a lower rate of 21.3% due to a favorable resolution reversal.

Strong H2 expected; 27 US launches and biosimilar catalysts ahead

• Strong H2 FY 2026-2027 guided — driven by semaglutide supply resumption in November, ongoing base business double-digit growth, and steady margin improvement; management expects the underlying base business (excluding lenalidomide) to deliver healthy double-digit growth across all key geographies.
• Management targets 27 product launches in the US for FY 2026-2027 — with a "reasonable" launch expected in Q2 FY 2026-2027 worth tens of millions of dollars (product name not disclosed).
• R&D spending guided at 7–8% of sales for FY 2026-2027 — focused on peptides, additional biosimilars, and "products targeting the 2034-2040 period," plus licensing and remediation.
• US tariff announcement on generics — management views it as an opening for discussion, noting that 25–30% of revenues are already manufactured by CMOs in the US, and expects dialogue between Indian IP and US associations to shape the outcome; not assigning significant weight at this stage.
• Management engaging in business development — across generics, innovation, and biosimilars, with several deals in discussion; cash on balance sheet of approximately Rs.3,000 Cr supports deal capacity.
• No penalty claims expected for supply failures — to Sandoz and Aspen based on contractual terms as of Q1 FY 2026-2027; the API for the product is supplied from the Vizag plant (C206), which received USFDA approval with no OAI issued in FY 2026-2027.